These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10496868)

  • 1. Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response.
    Steeghs L; Kuipers B; Hamstra HJ; Kersten G; van Alphen L; van der Ley P
    Infect Immun; 1999 Oct; 67(10):4988-93. PubMed ID: 10496868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.
    Fransen F; Boog CJ; van Putten JP; van der Ley P
    Infect Immun; 2007 Dec; 75(12):5939-46. PubMed ID: 17908810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.
    Verheul AF; Van Gaans JA; Wiertz EJ; Snippe H; Verhoef J; Poolman JT
    Infect Immun; 1993 Jan; 61(1):187-96. PubMed ID: 8418041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical contribution of both CD28 and ICOS in the adjuvant activity of Neisseria meningitidis H44/76 LPS and lpxL1 LPS.
    van Berkel ME; Schrijver EH; van Mourik A; Tesselaar K; van der Ley P; Steeghs L; Oosterwegel MA
    Vaccine; 2007 Jun; 25(24):4681-8. PubMed ID: 17499399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens.
    Nagaputra JC; Rollier CS; Sadarangani M; Hoe JC; Mehta OH; Norheim G; Saleem M; Chan H; Derrick JP; Feavers I; Pollard AJ; Moxon ER
    Clin Vaccine Immunol; 2014 Feb; 21(2):234-42. PubMed ID: 24351756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.
    Mehta OH; Norheim G; Hoe JC; Rollier CS; Nagaputra JC; Makepeace K; Saleem M; Chan H; Ferguson DJ; Jones C; Sadarangani M; Hood DW; Feavers I; Derrick JP; Pollard AJ; Moxon ER
    PLoS One; 2014; 9(12):e115713. PubMed ID: 25545241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.
    Arenas J; van Dijken H; Kuipers B; Hamstra HJ; Tommassen J; van der Ley P
    Clin Vaccine Immunol; 2010 Apr; 17(4):487-95. PubMed ID: 20107001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity.
    van der Ley P; Steeghs L; Hamstra HJ; ten Hove J; Zomer B; van Alphen L
    Infect Immun; 2001 Oct; 69(10):5981-90. PubMed ID: 11553534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis.
    de Jonge MI; Vidarsson G; van Dijken HH; Hoogerhout P; van Alphen L; Dankert J; van der Ley P
    Infect Immun; 2003 May; 71(5):2331-40. PubMed ID: 12704102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune responses of meningococcal B outer membrane vesicles in middle-aged mice.
    Trzewikoswki de Lima G; Rodrigues TS; Portilho AI; Correa VA; Gaspar EB; De Gaspari E
    Pathog Dis; 2020 Jul; 78(5):. PubMed ID: 32639524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins.
    de Jonge MI; Hamstra HJ; Jiskoot W; Roholl P; Williams NA; Dankert J; van Alphen L; van der Ley P
    Vaccine; 2004 Sep; 22(29-30):4021-8. PubMed ID: 15364452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives.
    Arigita C; Luijkx T; Jiskoot W; Poelen M; Hennink WE; Crommelin DJ; Ley Pv; Els Cv; Kersten GF
    Vaccine; 2005 Oct; 23(43):5091-8. PubMed ID: 15993990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neisseria meningitidis lipopolysaccharide modulates the specific humoral immune response to neisserial porins but has no effect on porin-induced upregulation of costimulatory ligand B7-2.
    Bhasin N; Ho Y; Wetzler LM
    Infect Immun; 2001 Aug; 69(8):5031-6. PubMed ID: 11447183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A.
    Zughaier S; Steeghs L; van der Ley P; Stephens DS
    Vaccine; 2007 May; 25(22):4401-9. PubMed ID: 17466419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models.
    Van De Verg LL; Hartman AB; Bhattacharjee AK; Tall BD; Yuan L; Sasala K; Hadfield TL; Zollinger WD; Hoover DL; Warren RL
    Infect Immun; 1996 Dec; 64(12):5263-8. PubMed ID: 8945575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
    Gorringe AR; Taylor S; Brookes C; Matheson M; Finney M; Kerr M; Hudson M; Findlow J; Borrow R; Andrews N; Kafatos G; Evans CM; Read RC
    Clin Vaccine Immunol; 2009 Aug; 16(8):1113-20. PubMed ID: 19553555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis.
    Hoogerhout P; Donders EM; van Gaans-van den Brink JA; Kuipers B; Brugghe HF; van Unen LM; Timmermans HA; ten Hove GJ; de Jong AP; Peeters CC
    Infect Immun; 1995 Sep; 63(9):3473-8. PubMed ID: 7543883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
    Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
    mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci.
    Jolley KA; Appleby L; Wright JC; Christodoulides M; Heckels JE
    Infect Immun; 2001 Jun; 69(6):3809-16. PubMed ID: 11349046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits.
    Cox AD; Zou W; Gidney MA; Lacelle S; Plested JS; Makepeace K; Wright JC; Coull PA; Moxon ER; Richards JC
    Vaccine; 2005 Oct; 23(43):5045-54. PubMed ID: 16046037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.